Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy

Cancer Treatment Reviews

Volumn 24, Issue 5, 1998, Pages 331-344

  Reed, E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; DNA ADDUCT; DNA REPAIR; DRUG RESISTANCE; ENZYME ACTIVITY; EXCISION REPAIR; HUMAN; REVIEW;

EID: 0031791029     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90056-1     Document Type: Article

References (97)

1. Poirier MC, Lippard SJ, Zwelling LA, Ushay HM, Kerrigan D, Thill CC, Santella RM, Grunberger D & Yuspa SH. Antibodies elicited against cis-diamminedichloroplatinum (II)-DNA adducts formed in vivo and in vitro. Proc. Natl. Acad. Sci. USA 1982; 79: 6443-6447.
2. Fichtinger-Schepman AMJ, Dijt FJ, De Jong WH, van Oosterom AR & Berends F. In vivo cis-Diamminedichloroplatinum(II)-DNA adduct formation and removal as measured with immunochemical techniques. In (M Nicolini, ed) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Martinus Nijhoff Publishing, Boston, 1988, pp 32-46.
3. Reed E, Sauerhoff S & Poirier MC. Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposure - A novel use of graphite furnace spectrometry. Atomic Spectroscopy 1988; 9: 93-95.
4. Perera FP, Tang D, Reed E, Parker RJ, Warburton D, O'Neill P, Albertini R, Bigbee W, Santella R, Tsai W-Y, Simon-Cereijido G, Randall C, Bosl G & Motzer R. Multiple biologic markers in testicular cancer patients treated with platinum-based chemotherapy. Cancer Res 1992; 52: 3558-3565.
5. Reed FP, Yuspa SH, Zwelling LA, Ozols RF & Poirier MC. Quantitation of cisplatin-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J. Clin. Invest. 1986; 77: 545-550.
6. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. USA 1987; 84: 5024-5028.
7. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 1988; 9: 1909-1911.
8. Reed E, Ostchega Y, Steinberg S, Yuspa SH, Young RC, Ozols RF & Poirier MC. An evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990; 50: 2256-2260.
9. Gupta-Burt S, Shamkhani H, Reed E, Tarone R, Allegra CJ, Pai L & Poirier MC. Correlation between patient response in ovarian, breast, and colon cancer and platinum drug-DNA adduct formation. Cancer Epidemiology, Biomarkers & Prevention 1993; 2: 229-234.
10. Poirier MC, Reed E, Litterst CL, Katz D & Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 1992; 52: 149-153.
11. Reed E, Gupta-Burt S, Litterst CL & Poirier MC. Characterization of the DNA damage recognized by an antiserum against cis-diamminedichloroplatinum (II)-modified DNA. Carcinogenesis 1990; 11: 2117-2121.
12. Fichtinger-Schepman AMJ, van der Velde-Bisser SD, van Kijk-Knijnenburg HCM, van Oosterom AT, Bann RA, Berends F. Kinetics of the formation and removal of cisplatin-DNA adduct in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990; 50: 7887-7894.
13. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM & Berends F. Cis-Diamminedichloroplatinum (II)-induced adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinu (II). Cancer Res 1987; 47: 3000-3004.
14. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, et al. Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay? Mutation Res 1987; 190: 59-62.
15. Motzer RJ, Reed E, Tang D, Shamkhani H, Poirier MC, Tsai W-Y, Parker RJ, Perera F & Bosi G. Platinum-DNA adducts assayed in leukocytes of germ cell tumor patients measured by atomic absorbance spectroscopy and enzyme linked immunosorbent assay. Cancer 1994; 73: 2843-2852.
16. Tang DL, Motzer RJ, Warburton D, O'Neill P, Albertini R, Bigbee W, Jensen RH, Bosl G & Perera FP. A study of five biological markers and clinical response in 36 testicular cancer patients treated with platinum-based chemotherapy. Proc. Am. Assoc. Cancer Res 1992; 33: 263, abst #1577.
17. Parker RJ, Gill I, Tarone R, Vionnet J, Grunberg S, Muggia F & Reed E. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis 1991; 12: 1253-1258.
18. Reed E, Parker RJ, Gill I, Bicher A, Dabholker M, Vionnet JA, Bostick-Bruton F, Tarone R & Muggia FM. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancy. Cancer Res 1993; 53: 3694-3699.
19. Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, Schmitz PI, Stoter G & Verweij J. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumor response in patients with solid tumors. Br J Cancer 1996; 73 (12): 1569-1575.
20. Reed E & Dabholkar M. Platinum-DNA adduct in vitro and in the clinic; comparisons of DNA damage levels and biologic effects. Environ Mol Mutagenesis 1996; 27 (Suppl. 27): 56.
21. Reed E, Dabholker M, Yunmbam MK & Jones L. Platinum-DNA adduct in vitro and in the clinic. Proc. Am. Assoc. Cancer Res 1998; 39: 505, abst #3436.
22. Parker RJ, Dimery IW, Dabholker M, Vionnet J & Reed E. Platinum-DNA adduct in head and neck cancer patients receiving cisplatin and carboplatin chemotherapy. International J. Oncol 1993; 3: 331-335.
23. Dabholkar M, Vionnet JA, Bostick-Bruton F, Yu JJ & Reed E. mRNA levels of XPAC and ERCC1 in ovarian tumor tissue correlates with response to platinum containing chemo-therapy. J. Clin. Invest 1994; 94: 703-708.
24. Van Duin M, de Wit J, Odijk H, Westerveld A, Yasui A, Koken HM, Hoeijmakers JH & Bootsma D. Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10. Cell 1986; 44: 913-923.
25. Sancer A. Mechanisms of DNA excision repair. Science 1994; 266: 1954-1956.
26. McWhir J, Selfridge J, Harrison DJ, Squires S & Melton DW. Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before wean-ing. Nature Genetics 1993; 5: 217-224.
27. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C & Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Nat'l. Cancer Inst. 1992; 84: 1512-1517.
28. Lee KB, Parker RJ, Bohr VA, Cornelison TC & Reed E. Cisplatin sensitivity/resistance in UV-repair deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993; 14: 2177-2180.
29. Yu JJ, Dabholkar M, Bennett W, Welsh JA, Mu C, Bostick-Bruton F, Vionnet JA & Reed E. Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between p53, ERCC1 and XPA. International J. of Oncology 1996; 8: 313-317.
30. Reed E. Ovarian cancer: molecular abnormalities. In (JR Bertino, ed) The Encyclopedia of Cancer, Academic Press, Inc., San Diego, 1996; 1192-1200.
31. Mu D, Park C-H, Matsunaga T, Hsu DS, Reardon JT & Sancar A. Reconstitution of human DNA Repair excision nuclease in a highly defined system. J. Biol. Chem. 1995; 270: 2415-2418.
32. Mu D, Hsu DS & Sancar A. Reaction mechanism of human DNA repair excision nuclease. J. Biol Chem. 1996; 271: 8285-8294.
33. States JC & Reed E. Enhanced XPA mRNA levels in cisplatinresistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Letters 1996; 108: 233-237.
34. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 1998; 16: 309-316.
35. Bitton RJ, Figg WD & Reed E. A preliminary risk-benefit assessment of paclitaxel. Drug Safety 1995; 12: 196-208.
36. Parker RJ, Dabholkar M, Lee KB, Bostick-Bruton F & Reed E. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. Monog. Nat'l. Cancer Inst. 1993; 15: 83-88.
37. Citardi MJ, Rowinsky EK & Donehower RC. Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine. Proc. Am. Assoc. Cancer Res. 1990; 31: 410, Abst #2431.
38. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J & Maher M. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: Molecular rationale and early clinical results. Seminars in Oncology 1995; 22: 90-96.
39. Kohn EC, Sarosy G, Davis P, Christian M, Ognibene FP, Sindelar WF, Jacob J, Steinberg SM, Premkumar A & Reed E. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecologic Oncol 1996; 62: 181-191.
40. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin; phase I/pharmacologic study. J. Clin. Oncol. 1991; 9: 1692-1703.
41. Reed E, Sarosy G, Kohn E, Christian M, Link C, Davis P, Maher M & Jacob J. A phase I study of paclitaxel and cytoxan in recurrent adenocarcinoma of the ovary. Gynecologic Oncology 1996; 61: 349-353.
42. Reed E. The chemotherapy of ovarian cancer. PPO Updates 1996; 10 (7): 1-12.
43. Zwelling LA, Anderson T & Kohn KW DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II)-diamminedichloride in L1210 mouse leukemia cells and its relation to cytotoxicity. Cancer Res 1979; 39: 365-369.
44. Plooy ACM, van Diik M & Lohman PHM. Induction and repair of DNA cross-links in Chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. Cancer Res 1984; 44: 2043-2051.
45. Reed E. Cisplatin. In (Pinedo HM, Chabner BA, Longo DL, eds) Cancer Chemotherapy and Biological Response Modifiers Annual - Volume II. Elsevier Science Publishers B.V., Amsterdam, pp 1990; 90-96.
46. Friedberg EC, Walker GC & Siede W. DNA Repair and Mutagenesis. ASM Press, Washington, D.C., 1995.
47. 6alkylguanine-DNA alkytransferase: regulation and importance of response to alkylating carcinogenesis and therapeutic agents. Cancer Res 1990; 50: 6119-6129.
48. 6alkylguanine-DNA alkytransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. Nucleic Acids Res 1988; 16: 679-6788.
49. Seeberg E, Eide L & Bjoras M. The base excision repair pathway. Trends Biochem. Sci. 1995; 20: 391-397.
50. Klungland A & Lindahl T. Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO Journal 1997; 16: 3341-3348.
51. Doroshow JH. Anthracyclines and anthracenediones. In (BA Chabner and DL Longo, eds); Cancer Chemotherapy and Biotherapy Principles and Practice, Lippincott-Raven, Philadelphia, 2nd ed, 1996, pp 409-434.
52. Sancar A & Sancar GB. Annu. Rev. Biochem. 1988; 57: 29-67.
53. Drapkin R, Sancar A & Reinberg D. Where transcription meets repair. Cell 1994; 77: 9-12.
54. Lee KB, Parker RJ & Reed E. Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance. Cancer Letters 1995; 88: 57-66.
55. Shivji MKK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992; 69: 367-374.
56. Van Vuuren AJ, Appeldoorn E, Odijk H, Humbert S, Moncollin V, Eker AP, Jaspers NG, Egly JM & Hoeijmakers JH. Partial characterization of the DNA repair protein complex containing the ERCC1, ERCC4, ERCC11 and XPF correcting activities. Mutation Res 1995; 337: 25-39.
57. Van Duin M, Koken MHM, van den Tol J, ten Dijke P, Odijk H, Westerveld A, Bootsma D & Hoeijmakers JHJ. Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res 1987; 15: 9195-9213.
58. Rolig RL, Adair GM & Nairn RS. Defective homologous recombination in a Chinese hamster ovary ERCC1 knock-out cell line. Proc. Am. Assoc. Cancer Res. 1998; 38: 461, abst #3138.
59. Dabholker M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA & Reed E. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutation Res 1993; 293: 151-160.
60. Dabholker MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ & Reed E. Malignant and non-malignant brain tissues differ in their mRNA expression patterns for ERCCl and ERCC2. Cancer Res 1995; 55: 1261-1266.
61. Dabholker MD, Berger MS, Vionnet JA, Overton L, Bostick-Bruton F, Yu JJ, Silber JR & Reed E. Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain. Molecular Carcinogenesis 1996; 17: 1-7.
62. Liang BC, Ross DA & Reed E. Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. J. Neuro-Oncol 1995; 226: 17-23.
63. Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E & Liang B. Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecologic Oncology 1997; 66: 3-40.
64. Karran P. Appropriate partners make good matches. Science 1995; 268: 1857-1858.
65. Modrich P. Mismatch repair, genetic stability and cancer. Science 1994; 266: 1959-1960.
66. Drummond JT, Li G-M, Longley MJ & Modrich ?. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science 1995; 268: 1909-1912.
67. Palombo F, Gallinari P, Iaccarino I, et al. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science 1995; 268: 1912-1914.
68. Drummond JT, Anthoney A, Brown R & Modrich P. Cisplatin and adriamycin resistance are associated with MutL-alpha and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 1996; 271: 19645-19648.
69. Wang XW, Harris CC. P53 Tumor-suppressor gene: clues to molecular carcinogenesis. J. Cell. Physiol. 1997; 173: 247-255.
70. Harris LC, Remack JS, Houghton PJ & Brent TP. Wild-type p53 suppresses transcription of the human O6-methylhuanine-DNA methyltransferase gene. Cancer Res 1996; 56: 2029-2032.
71. Kastan MB, Canman CE & Leonard CJ. p53, Cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14: 3-xx.
72. Righetti SC, Torre GD, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-693.
73. Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/ M arrest and apoptosis. Nature Med. 1996; 2: 72-79.
74. Reed E. "Platinum Analogs"; Section 7 of Chapter 18-"Anticancer Drugs". In: (DeVita, VT, Hellman S, Rosenberg SA, eds.), Cancer Principles and Practice of Oncology, Lippincott, Philadelphia, 1993; pp 390-400.
75. Reed E, Dabholkar M & Chabner BA. Platinum Analogues. In: Chabner BA and Longo DL (eds.) Cancer Chemotherapy (2nd ed.); Lippincott-Raven Publishers, Philadelphia, 1996; 357-378.
76. Eastman A, Schulte N, Sheibani N & Sorenson CM. Mechanisms of resistance to platinum drugs. In: (Nicolini M, ed.) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Martinus Nijhoff Publishing, Boston, 1988, pp 178-196.
77. Parker RJ, Eastman A, Bostick-Bruton F & Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 1991; 87: 772-777.
78. Dabholkar M, Parker R & Reed E. Determinants of cisplatin sensitivity in non-malignant, non-drug-selected human T cell lines. Mutation Res. 1992; 274 (1): 45-56.
79. Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM & Reed E. Cisplatin-DNA adduct damage and repair in peripheral blood leukocytes: in vivo and in vitro. Environmental Health Perspectives 1992; 93: 53-59.
80. Godwin AK, Meister A, O'Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci USA 1992; 89: 3070-3074.
81. Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC & Ozols RF. Glutathione and drug resistance. Cancer Invest. 1996; 14: 158-168.
82. Jones JC, Zhen W, Reed E, Parker RJ, Sancar A & Bohr VA. Preferential DNA repair of cisplatin lesions in active genes in CHO cells. J. Biol Chem. 1991; 266: 7101-7107.
83. Zhen W, Link Jr AK, O'Connor PM, Reed E, Parker RJ, Howell SB & Bohr VA. Increased gene-specific repair of cisplatin interstrand crosslinks in cisplatin resistant human ovarian cancer cells. Mol. and Cell Biol. 1992; 12: 3689-3698.
84. Weeda G, van Ham RCA, Vermeulen W, Bootsma D, van der Eb AJ & Hoeijmakers JHJ. A presumed DNA helicase encoded by ERCC3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome Cell 1990; 62: 777-791.
85. Park C-H, Sancar A. Formation of a ternary complex by human XPA, ERCC1, and ERCC4 (XPF) excision repair proteins. Proc. Natl. Acad. Sci. USA 1994; 91: 5017-5021.
86. Li L, Elledge SJ, Peterson CA, Balses ES, Legerski RJ. Specific association between the human DNA repair proteins XPA and ERCC1. Proc. Natl. Acad. Sci. USA 1994; 91: 5012-5016.
87. Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D & Hoeijmakers JHJ. ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes. Cell 1992; 71: 939-953.
88. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R & Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996; 56 (13): 3087-3090.
89. Li Q, Tsang B, Dabholkar M, Bostick-Bruton F & Reed E. Cisplatin induces ERCC2 mRNA and ERCC1 protein in A2780/CP70 human ovarian cancer cells. Proc. Am. Assoc. Cancer Res. 1999; 39: 241, abst#1649.
90. Dabholkar M, Vionnet J, Parker RJ, Bostick-Bruton F, Dobbins A & Reed E. Expression of an alternatively spliced ERCC1 mRNA species, is related to reduced DNA repair efficiency in human T lymphocytes. Oncology Reports 1995; 2: 209-214.
91. Yu JJ, Reed EL, Mu C, Bostick-Bruton F & Reed E. Demonstration of a polymorphism in the gene ERCC1 by two DNA sequencing methods. Oncology Reports 1997; 4: 905-907.
92. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC & Reed E. A nucleotide polymorphism in ERCC1 gene in human ovarian cancer cell lines and tumor tissues. Mutation Research Genomics 1997; 382: 13-20.
93. Yu JJ, Mu C, Dabholkar M, Bostick-Bruton F, & Reed E. Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. International J. Molecular Med. 1998; 1: 617-620.
94. Perkins AS & Vande Woude GF. Principles of molecular cell biology of cancer; oncogenes. In: (DeVita VT, Hellman S, Rosenberg SA, eds.), Cancer Principles and Practice of Oncology, Lippincott, Philadelphia, 1993; pp 35-59.
95. Dabholkar M & Reed E. Letter to the Editor (related to 95, above). Cancer Res. 1995; 55: 3933-3934.
96. Dabholkar M, Vionnet T, Bostick-Bruton F, et al. Nucleotide excision repair mediates clinical resistance to platinum compounds in human ovarian cancer. Proc. Am. Assoc. Cancer Res. 1995; 36: 217, abst 1295.
97. Reed E, Dabholkar M, Thompson C & Bostick-Bruton F. Evidence for "order" in the appearance of mRNAs of nucleotide excision repair genes in human ovarian cancer tissues. Submitted, 1998.